Cited by 201Fatty Acid Research and HealthLipid metabolism and disordersLipoproteins and Cardiovascular Health

The DOI matches its Crossref record; 96 of the 97 references it cites were found in a registry or an index.

The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia

Open access

Backes, James, Anzalone, Deborah, Hilleman, Daniel, Catini, Julia·2016·Lipids in Health and Disease

DOI 10.1186/s12944-016-0286-4PMC PMC4957330

Open this paper in CoChat — free account Open PDF

Abstract

Hypertriglyceridemia (triglycerides > 150 mg/dL) affects ~25 % of the United States (US) population and is associated with increased cardiovascular risk. Severe hypertriglyceridemia (≥ 500 mg/dL) is also a risk factor for pancreatitis. Three omega-3 fatty acid (OM3FA) prescription formulations are approved in the US for the treatment of adults with severe hypertriglyceridemia: (1) OM3FA ethyl esters (OM3EE), a mixture of OM3FA ethyl esters, primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (Lovaza®, Omtryg™, and generics); (2) icosapent ethyl (IPE), EPA ethyl esters (Vascepa®); and (3) omega-3 carboxylic acids (OM3CA), a mixture of OM3FAs in free fatty acid form, primarily EPA, DHA, and docosapentaenoic acid (Epanova®). At approved doses, all formulations substantially reduce triglyceride and very-low-density lipoprotein levels. DHA-containing formulations may also increase low-density lipoprotein cholesterol. However, this is not accompanied by increased non-high-density lipoprotein cholesterol, which is thought to provide a better indication of cardiovascular risk in this patient population. Proposed mechanisms of action of OM3FAs include inhibition of diacylglycerol acyltransferase, increased plasma lipoprotein lipase activity, decreased hepatic lipogenesis, and increased hepatic β-oxidation. OM3CA bioavailability (area under the plasma concentration-time curve from zero to the last measurable concentration) is up to 4-fold greater than that of OM3FA ethyl esters, and unlike ethyl esters, the absorption of OM3CA is not dependent on pancreatic lipase hydrolysis. All three formulations are well tolerated (the most common adverse events are gastrointestinal) and demonstrate a lack of drug-drug interactions with other lipid-lowering drugs, such as statins and fibrates. OM3FAs appear to be an effective treatment option for patients with severe hypertriglyceridemia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1186/s12944-016-0286-4

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Fig. 1 Proposed mechanisms of action of prescription formulations of long-chain omega-3 fatty acids. ApoCIII apolipoprotein CIII, Acetyl Co-A acetyl coenzyme A, DGAT diglyceride acyltransferase; FA fatty acid, LPL lipoprotein lipase, TG triglyceride, VLDL very-low-density lipoproteinCC BY · PubMed Central

Fig. 2 TG reduction observed with varying doses of omega-3 carboxylic acids, omega-3 ethyl esters, and icosapent ethyl in (a) patients with severe hypertriglyceridemia (TG ≥ 500 mg/dL) [14, 16, 17] and (b) statin-treated patients with high baseline TG levels (TG level ≥ 200 mg/dL and < 500 mg/dL) [20, 21, 24] Data not available for OM3EE at 2 g/day. OM3CA = Percentage change from baseline expressed as least-squares geometric mean; OM3EE = percentage change from baseline expressed as geometric mean; IPE = percentage change from baseline expressed as median. †Placebo used = olive oil; ‡Placebo used = vegetable oil; §Placebo used = mineral oil; ǁPlacebo used = corn oil; ¶Placebo not specified. IPE icosapent ethyl, OM3CA omega-3 carboxylic acids, OM3EE omega-3 ethyl esters, TG triglycerideCC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
(2002) · Circulation · doi:10.1161/circ.106.25.3143 · Cited by 14,092
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Standards of Medical Care in Diabetes
Power, D. V. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,676
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease
Kris-Etherton, P. M., Harris, W. S., & Appel, L. J. (2002) · Circulation · doi:10.1161/01.cir.0000038493.65177.94 · Cited by 3,707
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Complementary and Alternative Medicine Use Among Adults and Children: United States, 2007
Barnes, P. M., Bloom, B. E., & Nahin, R. L. (2008) · PsycEXTRA Dataset · doi:10.1037/e623942009-001 · Cited by 3,144
Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report
Kavey, R., Simons-Morton, D., & de Jesus, J. D. (2011) · Pediatrics · doi:10.1542/peds.2009-2107c · Cited by 2,131
Fish Intake, Contaminants, and Human Health: Evaluating the Risks and the Benefits
Mozaffarian, D., & Rimm, E. B. (2006) · JAMA · doi:10.1001/jama.296.15.1885 · Cited by 1,966
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Arzneimittelforschung
(2017) · Arzneimittelforschung · doi:10.1055/s-00000175 · Cited by 1,134
Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887 · cited 2×
“Like the 2014 NLA guideline, a number of other guidelines pertaining to the treatment and management of hypertriglyceridemia also recommend the use of TGlowering drugs (including high-dose OM3FAs), alone or in combination with statin therapy, in patients who continue to have elevated TG or non-HDL-C levels despite bei…”
BackgroundMethod
Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review
Balk, E. M., Lichtenstein, A. H., Chung, M., Kupelnick, B., Chew, P., & Lau, J. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.02.012 · Cited by 732
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management
Hegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70191-8 · Cited by 635
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial
Miller, M., Cannon, C. P., Murphy, S. A., Qin, J., Ray, K. K., & Braunwald, E. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.10.038 · Cited by 610
Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice
Horton, J. D., Bashmakov, Y., Shimomura, I., & Shimano, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.5987 · Cited by 577
DHA Effects in Brain Development and Function
Lauritzen, L., Brambilla, P., Mazzocchi, A., Harsløf, L. B. S., Ciappolino, V., & Agostoni, C. V. (2016) · Nutrients · doi:10.3390/nu8010006 · Cited by 566
American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis
Jellinger, P. S., Smith, D. A., Mehta, A., Ganda, O. P., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., & Seibel, J. A. (2012) · Endocrine Practice · doi:10.4158/ep.18.s1.1 · Cited by 533
National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.07.007 · Cited by 469
Safety considerations with fibrate therapy
Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408
Docosahexaenoic Acid but Not Eicosapentaenoic Acid Lowers Ambulatory Blood Pressure and Heart Rate in Humans
Mori, T. A., Bao, D. Q., Burke, V., Puddey, I. B., & Beilin, L. J. (1999) · Hypertension · doi:10.1161/01.hyp.34.2.253 · Cited by 407
Why do omega-3 fatty acids lower serum triglycerides?
Harris, W. S., & Bulchandani, D. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000236363.63840.16 · Cited by 398
Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study
Davidson, M. H., Stein, E. A., Bays, H. E., Maki, K. C., Doyle, R. T., Shalwitz, R. A., Ballantyne, C. M., & Ginsberg, H. N. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.018 · Cited by 385
Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial)
Bays, H. E., Ballantyne, C. M., Kastelein, J. J., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.04.015 · Cited by 358
Nutraceuticals and dyslipidaemia: Beyond the common therapeutics
Scicchitano, P., Cameli, M., Maiello, M. R., Modesti, P. A., Muiesan, M. L., Novo, S., Palmiero, P., Saba, P. S., Pedrinelli, R., & Ciccone, M. M. (2014) · Journal of Functional Foods · doi:10.1016/j.jff.2013.12.006 · Cited by 354
Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance
Park, Y., & Harris, W. S. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m200282-jlr200 · Cited by 348
Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)
Ballantyne, C. M., Bays, H. E., Kastelein, J. J., Stein, E., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.05.031 · Cited by 342
Low-Density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy
Grundy, S. M. (2002) · Circulation · doi:10.1161/01.cir.0000038419.53000.d6 · Cited by 309
Safety and Efficacy of Omacor in Severe Hypertriglyceridemia
Harris, W. S., Ginsberg, H. N., Arunakul, N., Shachter, N. S., Windsor, S. L., Adams, M., Berglund, L., & Osmundsen, K. (1997) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182679700400511 · Cited by 306
Effects of Eicosapentaenoic Acid Versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-Analysis
Wei, M. Y., & Jacobson, T. A. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0210-3 · Cited by 284
Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins
Schwartz, G. G., Abt, M., Bao, W., DeMicco, D., Kallend, D., Miller, M., Mundl, H., & Olsson, A. G. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.544 · Cited by 272
Safety considerations with niacin therapy
Guyton, J. R., & Bays, H. E. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.018 · Cited by 269
Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications
Bays, H. E., Tighe, A. P., D, R. S. M., & Davidson, M. H. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.3.391 · Cited by 267
Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review
Jacobson, T. A., Glickstein, S. B., Rowe, J. D., & Soni, P. N. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.10.018 · Cited by 263
Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease
Rosenson, R. S., Davidson, M. H., Hirsh, B. J., Kathiresan, S., & Gaudet, D. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.042 · Cited by 260
Safety and efficacy of Omacor in severe hypertriglyceridemia
Harris, W. S., Ginsberg, H. N., Arunakul, N., Shachter, N. S., Windsor, S. L., Adams, M., Berglund, L., & Osmundsen, K. (1997) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199710000-00011 · Cited by 252
Eicosapentaenoic acid (EPA) from highly concentrated n−3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability
Cawood, A. L., Ding, R., Napper, F. L., Young, R. H., Williams, J. A., Ward, M. J., Gudmundsen, O., Vige, R., Payne, S. P. K., Ye, S., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.05.022 · Cited by 249
An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia
Durrington, P. N. (2001) · Heart · doi:10.1136/heart.85.5.544 · Cited by 243
Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA
Albert, B. B., Derraik, J. G. B., Cameron-Smith, D., Hofman, P. L., Tumanov, S., Villas-Boas, S. G., Garg, M. L., & Cutfield, W. S. (2015) · Scientific Reports · doi:10.1038/srep07928 · Cited by 238
Safety Considerations with Omega-3 Fatty Acid Therapy
Bays, H. E. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.020 · Cited by 235
Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial
Kastelein, J. J. P., Maki, K. C., Susekov, A., Ezhov, M., Nordestgaard, B. G., Machielse, B. N., Kling, D., & Davidson, M. H. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.10.003 · Cited by 233
Long chain polyunsaturated fatty acid supplementation in infant formula and blood pressure in later childhood: follow up of a randomised controlled trial
Forsyth, J. S., Willatts, P., Agostoni, C., Bissenden, J., Casaer, P., & Boehm, G. (2003) · BMJ · doi:10.1136/bmj.326.7396.953 · Cited by 232
Carboxyl ester lipase
Hui, D. Y., & Howles, P. N. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r200013-jlr200 · Cited by 226
Serum Fatty Acids and the Risk of Coronary Heart Disease
Simon, J. A., Hodgkins, M. L., Browner, W. S., Neuhaus, J. M., Bernert, J. T., & Hulley, S. B. (1995) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117662 · Cited by 212
Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients
Woodman, R. J., Mori, T. A., Burke, V., Puddey, I. B., Barden, A. E., Watts, G. F., & Beilin, L. J. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00307-6 · Cited by 198
Clinical nutrition: 4. Omega-3 fatty acids in cardiovascular care.
Holub, B. J. (2002) · PubMed Central · Cited by 197
Expert Opinion: Omega-3 Fatty Acids and Bleeding—Cause for Concern?
Harris, W. S. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.021 · Cited by 191
A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: The ECLIPSE (Epanova® compared to Lovaza® in a pharmacokinetic single-dose evaluation) study
Davidson, M. H., Johnson, J., Rooney, M. W., Kyle, M. L., & Kling, D. F. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.01.002 · Cited by 191
Correlation of serum triglyceride and its reduction by ω-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins
Pownall, H. J., Brauchi, D., Kilinç, C., Osmundsen, K., Pao, Q., Payton-Ross, C., Gotto, A. M., & Ballantyne, C. M. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(98)00301-3 · Cited by 179
Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy
Stark, K. D., & Holub, B. J. (2004) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/79.5.765 · Cited by 177
Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia
Chan, D. C., Watts, G. F., Barrett, P. H. R., Beilin, L. J., Redgrave, T. G., & Mori, T. A. (2002) · Diabetes · doi:10.2337/diabetes.51.8.2377 · Cited by 160
Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: results from the EARLY Study
Engler, M. M., Engler, M. B., Malloy, M. J., Chiu, E., Besio, D., Paul, S. M., Stuehlinger, M., Morrow, J. D., Ridker, P. M., Rifai, N., et al. (2004) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp42672 · Cited by 150
Dietary long-chain n-3 PUFAs increase LPL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype
Khan, S., Minihane, A.-M., Talmud, P. J., Wright, J. W., Murphy, M. C., Williams, C. M., & Griffin, B. A. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30473-9 · Cited by 145
Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies
Bays, H. E., Ballantyne, C. M., Braeckman, R. A., Stirtan, W. G., & Soni, P. N. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-012-0002-3 · Cited by 141
Fish Oil for the Treatment of Cardiovascular Disease
Weitz, D., Weintraub, H., Fisher, E., & Schwartzbard, A. Z. (2010) · Cardiology in Review · doi:10.1097/crd.0b013e3181ea0de0 · Cited by 138
Blood concentrations of individual long-chain n–3 fatty acids and risk of nonfatal myocardial infarction
Sun, Q., Ma, J., Campos, H., Rexrode, K. M., Albert, C. M., Mozaffarian, D., & Hu, F. B. (2008) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/88.1.216 · Cited by 132
Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials
Filion, K. B., Khoury, F. E., Bielinski, M., Schiller, I., Dendukuri, N., & Brophy, J. M. (2010) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-10-24 · Cited by 124
Digestion and lymphatic transport of eicosapentaenoic and docosahexaenoic acids given in the form of triacylglycerol, free acid and ethyl ester in rats
Ikeda, I., Sasaki, E., Yasunami, H., Nomiyama, S., Nakayama, M., Sugano, M., Imaizumi, K., & Yazawa, K. (1995) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(95)00180-8 · Cited by 110
Involvement of Lipoxygenase Pathway in Docosapentaenoic Acid-Induced Inhibition of Platelet Aggregation.
Akiba, S., MURATA, T., Kitatani, K., & Sato, T. (2000) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.23.1293 · Cited by 108
A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial)
Maki, K. C., Orloff, D. G., Nicholls, S. J., Dunbar, R. L., Roth, E. M., Curcio, D., Johnson, J., Kling, D., & Davidson, M. H. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.07.420 · Cited by 104
Rosuvastatin-Associated Adverse Effects and Drug-Drug Interactions in the Clinical Setting of Dyslipidemia
Kostapanos, M. S., Milionis, H. J., & Elisaf, M. (2010) · American Journal of Cardiovascular Drugs · doi:10.2165/13168600-000000000-00000 · Cited by 103
Very long chain N-3 fatty acids intake and carotid atherosclerosis
Hino, A., Adachi, H., Toyomasu, K., Yoshida, N., Enomoto, M., Hiratsuka, A., Hirai, Y., Satoh, A., & Imaizumi, T. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.04.020 · Cited by 102
Omega-3 polyunsaturated fatty acid has an anti-oxidant effect via the Nrf-2/HO-1 pathway in 3T3-L1 adipocytes
楠知里, Liu, Y., Yoshizaki, T., Nakagawa, F., Ishikado, A., Kondo, M., Morino, K., Sekine, O., Ugi, S., Nishio, Y., et al. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.10.115 · Cited by 95
Hepatic farnesyl diphosphate synthase expression is suppressed by polyunsaturated fatty acids
Jossic-Corcos, C. L., Gonthier‐Guéret, C., Zaghini, I., Logette, E., Shechter, I., & Bournot, P. (2005) · Biochemical Journal · doi:10.1042/bj20040933 · Cited by 90
Low-Dose Docosahexaenoic Acid Lowers Diastolic Blood Pressure in Middle-Aged Men and Women1
Theobald, H. E., Goodall, A. H., Sattar, N. A., Talbot, D. C. S., Chowienczyk, P., & Sanders, T. A. B. (2007) · Journal of Nutrition · doi:10.1093/jn/137.4.973 · Cited by 89
Omega-3 fatty acids
Davidson, M. H. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000019 · Cited by 88
Impact of omega-3 polyunsaturated fatty acids on coronary plaque instability: An integrated backscatter intravascular ultrasound study
Amano, T., Matsubara, T., Uetani, T., Kato, M., Kato, B., Yoshida, T., Harada, K., Kumagai, S., Kunimura, A., Shinbo, Y., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.05.030 · Cited by 83
Plasma essential fatty acids, cigarette smoking, and dietary antioxidants in peripheral arterial disease. A population-based case-control study.
Leng, G. C., Horrobin, D. F., Fowkes, F. G. R., Smith, F. B., Lowe, G. D. O., Donnan, P. T., & Ells, K. (1994) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.14.3.471 · Cited by 76
Overview of Prescription Omega-3 Fatty Acid Products for Hypertriglyceridemia
WEINTRAUB, H. S. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.11.2828 · Cited by 74
Hypertriglyceridemia-induced recurrent acute pancreatitis: A case-based review
Kota, S., Kota, S. K., Jammula, S., Krishna, S., & Modi, K. (2012) · Indian journal of endocrinology and metabolism · doi:10.4103/2230-8210.91211 · Cited by 70
Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: A review of the literature
Ito, M. K. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.012 · Cited by 68
Trends in elevated triglyceride in adults: United States, 2001-2012.
Carroll, M. D., Kit, B. K., & Lacher, D. A. (2015) · PubMed · Cited by 64
Impaired Fetal Growth and Arterial Wall Thickening: A Randomized Trial of Omega-3 Supplementation
Skilton, M. R., Ayer, J. G., Harmer, J. A., Webb, K., Leeder, S., Marks, G. B., & Celermajer, D. S. (2012) · PEDIATRICS · doi:10.1542/peds.2011-2472 · Cited by 62
[Comparative bioavailability of eicosapentaenoic acid and docasahexaenoic acid from triglycerides, free fatty acids and ethyl esters in volunteers].
Beckermann, B., Beneke, M., & Seitz, I. (1990) · PubMed · Cited by 61
High Intake of Dietary Long-Chain ω-3 Fatty Acids Is Associated With Lower Blood Pressure in Children Born With Low Birth Weight
Skilton, M. R., Raitakari, O. T., & Celermajer, D. S. (2013) · Hypertension · doi:10.1161/hypertensionaha.111.01030 · Cited by 59
Complexities of plasma apolipoprotein C-III metabolism
Frank M. Sacks, E. B., Zheng, C., & Jeffrey S. Cohn, E. B. (2011) · Journal of Lipid Research · doi:10.1194/jlr.e015701 · Cited by 54
Effects of Prescription Omega-3-Acid Ethyl Esters on Non—High-Density Lipoprotein Cholesterol When Coadministered With Escalating Doses of Atorvastatin
Bays, H. E., McKenney, J., Maki, K. C., Doyle, R. T., Carter, R. N., & Stein, E. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0397 · Cited by 54
The Synthesis of Fatty Acid Ethyl Ester by Carboxylester Lipase
Tsujita, T., & Okuda, H. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.tb19994.x · Cited by 49
Study of the Pharmacokinetic Interaction Between Simvastatin and Prescription Omega‐3‐Acid Ethyl Esters
McKenney, J. M., Swearingen, D., Spirito, M. D., Doyle, R. T., Pantaleon, C., Kling, D. F., & Shalwitz, R. A. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006289849 · Cited by 40
Docosahexaenoic acid enrichment can reduce L929 cell necrosis induced by tumor necrosis factor
Kishida, E., Tajiri, M., & Masuzawa, Y. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2006.03.023 · Cited by 40
Antiarrhythmic effects of free polyunsaturated fatty acids in an experimental model of LQT2 and LQT3 due to suppression of early afterdepolarizations and reduction of spatial and temporal dispersion of repolarization
Milberg, P., Frommeyer, G., Kleideiter, A., Fischer, A., Osada, N., BREITHARDT, G. E., Fehr, M., & Eckardt, L. (2011) · Heart Rhythm · doi:10.1016/j.hrthm.2011.03.058 · Cited by 39
Long Chain Omega-3 Dietary Supplements: A Review of the National Library of Medicine Herbal Supplement Database
Zargar, A., & Ito, M. K. (2011) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2011.0004 · Cited by 39
Eicosapentaenoic Acid Improves Endothelial Function in Hypertriglyceridemic Subjects Despite Increased Lipid Oxidizability
Okumura, T., Fujioka, Y., Morimoto, S., Tsuboi, S., Masai, M., Tsujino, T., Ohyanagi, M., & Iwasaki, T. (2002) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200211000-00003 · Cited by 37
The effect of omega-3 carboxylic acids on apolipoprotein CIII−containing lipoproteins in severe hypertriglyceridemia
Morton, A. M., Furtado, J. D., Lee, J., Amerine, W., Davidson, M. H., & Sacks, F. M. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.09.005 · Cited by 32
Early Impact of Prescription Omega-3 Fatty Acids on Platelet Biomarkers in Patients with Coronary Artery Disease and Hypertriglyceridemia
Serebruany, V. L., Miller, M. J., Pokov, A. N., Lynch, D., Jensen, J. K., Hallén, J., & Atar, D. (2011) · Cardiology · doi:10.1159/000329300 · Cited by 31
Beneficial Effects of Omega-3 Fatty Acids on Low Density Lipoprotein Particle Size in Patients with Type 2 Diabetes Already under Statin Therapy
Lee, M. W., Park, J. K., Hong, J. W., Kim, K. J., Shin, D. Y., Ahn, C. W., Song, Y. D., Cho, H. K., Park, S. W., & Lee, E. J. (2013) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2013.37.3.207 · Cited by 30
The Role of Omega-3 Polyunsaturated Fatty Acids Supplementation in Childhood: A Review
Ciccone, M. M., Scicchitano, P., Gesualdo, M., Zito, A., Carbonara, S., Ricci, G., Cortese, F., & Giordano, P. (2013) · Recent Advances in Cardiovascular Drug Discovery (Formerly Recent Patents on Cardiovascular Drug Discovery) · doi:10.2174/1574890111308010006 · Cited by 28
Effect of omega-3-acid ethyl esters on the steady-state plasma pharmacokinetics of rosuvastatin in healthy adults
Gosai, P., Liu, J., Doyle, R. T., Johnson, J., Carter, R., Sica, D. A., & McKenney, J. M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802532640 · Cited by 25
Phase 1 Study of the Effect of Icosapent Ethyl on Warfarin Pharmacokinetic and Anticoagulation Parameters
Braeckman, R., Stirtan, W., & Soni, P. N. (2014) · Clinical drug investigation · doi:10.1007/s40261-014-0194-1 · Cited by 19
Effect of omega-3-acid ethyl esters on steady-state plasma pharmacokinetics of atorvastatin in healthy adults
Spirito, M. D., Morelli, G., Doyle, R., Johnson, J., & McKenney, J. M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802233827 · Cited by 18
Omega-3 oil: fish or pills?
(2003) · PubMed · Cited by 2

Sorted by citations

The Short Overview on the Relevance of Fatty Acids for Human Cardiovascular Disorders
Шрамко, В. С., Polonskaya, Y. V., Kashtanova, E. V., Stakhneva, E. M., & Ragino, Y. I. (2020) · Biomolecules · doi:10.3390/biom10081127 · Cited by 221
Intake of ω-3 polyunsaturated fatty acids in patients with rheumatoid arthritis: A systematic review and meta-analysis
Gioxari, A., Kaliora, A. C., Marantidou, F., & Panagiotakos, D. P. (2017) · Nutrition · doi:10.1016/j.nut.2017.06.023 · Cited by 203
Therapeutic potential of omega-3 fatty acid-derived epoxyeicosanoids in cardiovascular and inflammatory diseases
Schunck, W., Konkel, A., Fischer, R., & Weylandt, K. H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.016 · Cited by 211
Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD(+) levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study
Dellinger, R. W., Santos, S. R., Morris, M., Evans, M., Alminana, D., Guarente, L., & Marcotulli, E. (2017) · npj Aging and Mechanisms of Disease · doi:10.1038/s41514-017-0016-9 · Cited by 181
Marine Natural Products in Clinical Use
Haque, N., Parveen, S., Tang, T., Wei, J., & Huang, Z. (2022) · Marine Drugs · doi:10.3390/md20080528 · Cited by 172

See all 201

Authors: Backes, J., Anzalone, D., Hilleman, D., & Catini, J.
Affiliations: University of Kansas (US)
AstraZeneca (United States) (US)
Creighton University (US)
Corresponding author: Backes, James
ORCID: Backes, James
Hilleman, Daniel
Venue: Lipids in Health and Disease
Publisher: Springer Science and Business Media LLC
Published: 2016-07-22
Volume: 15
Issue: 1
Pages: 118-118
ISSN: 1476-511X (ISSN-L)
DOI: 10.1186/s12944-016-0286-4
PMC: PMC4957330
OpenAlex: W2487890137
Cited by: 195
References: 97
Citations by year: 2026: 8 · 2025: 20 · 2024: 20 · 2023: 20 · 2022: 26 · 2021: 29 · 2020: 25 · 2019: 15 · 2018: 9 · 2017: 20 · 2016: 1
FWCI: 2.01
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
Locations: Lipids in Health and Disease (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Creighton Digital Repository (CDR) (submittedVersion)
KU ScholarWorks (The University of Kansas) (submittedVersion, cc-by)
Funders: AstraZeneca
Topics: Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords: omega-3 fatty acids, severe hypertriglyceridemia, triglyceride-lowering therapy, icosapent ethyl, eicosapentaenoic acid, docosahexaenoic acid, docosapentaenoic acid, VLDL, non-HDL cholesterol, lipoprotein lipase, hepatic lipogenesis, fatty acid beta-oxidation, bioavailability, drug-drug interactions, cardiovascular risk, pancreatitis
MeSH terms: Adult, Hypolipidemic Agents, Biological Availability, Docosahexaenoic Acids, Drug Combinations, Esters, Humans, Lipoprotein Lipase, Cholesterol, LDL, Lipoproteins, VLDL, Liver, Oxidation-Reduction, Triglycerides, Eicosapentaenoic Acid, Hypertriglyceridemia, Fatty Acids, Omega-3, Lipogenesis, Diacylglycerol O-Acyltransferase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks